The efficacy of MEKi against most EP-TF risk genes in NB further aligned with previous studies, suggesting that MEK inhibition could mitigate EP-TF related oncogenic alterations in high-grade ovarian cancer (Machino et al., 2023) and lung cancer (Li et al., 2019) and counteract resistance to chemoimmunotherapy. This evidence concerns the gene MAP2K7 and lung carcinoma.